Slide 1: Corporate Presentation March 2026
£ipca A dose of life Ipca Laborate Corporate Presentation March 2026
Slide 2: About Us
About Us a OOCOE Incorporation “Consolidated income Export to >16,000 | 70+ | FY 2025-26 = =69400+ | Employees . Wonseuing L years RO, 821 as countries with | sites ' labs USS1, 109 wn, wine |
Slide 3: Our Values
Our Values a wae Qualiti Safeti Integriti | Digniti _— Responsibilit’ Adhere to Ensure safety Comply with Value Facilitate good standards comes first : ethics & standards; people : business practices
Slide 4: Five Years' Highlights
Five Years’ Highlights (won ~\ Standalone %6,277.75 Yana 277. 797.50) zone 35,925.81 ($757.82) aa 5,491.22 ($738.69) 6000 ($737.38) 4,301.96 5000 %3,940.25 ($485.82) 3,570.05 (5465.59) 3,282.39 4000 | =) 983.09 (5409.17) SHES) (5400.58) 3000 = 9 .P —-O— ws %3,129.43 2000 %2,508.13 € 2,643.42 2,707.7
Slide 5: Five Years' Highlights
Five Years’ Highlights NX 7,829.81 %9,820.78 (5945.17) 9,032.39 ($1,109.07) %6,369.94 ($1,067.28) 5,896.36 ($794.06) ($791.78) 5,255.33 4,894.16 ($593.49) 4089.87 ($578.30) $493.71 3,077.75 ro eal) (Ca) = T4,565.45 4,138.23 ($515.58) 6 aioe (5488.98) 451.47) 22,818.61 2,978.88 ( Gana ($371.34) 7 o—
Slide 6: Slide 6
Slide 7: Manufacturing Sites - Formulations
B® Formulations @® rep B® Biotech WD Corporate Office IpcaLaboratories *Unichem Overseas Pisgah Labs (Pisgah, NC) Indore Cluster Pithampur(SEZ). . SilvassaCluster & Kandla wiacum Mumbai Cluster Manufacturing Sites & Badd (2 facilities) & Dehradun (2 facilities) Ratam Formulations Ghaziabad & Joretha
Slide 8: Manufacturing Sites - Formulations
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry Syrups Tablets & Capsules Table
Slide 9: Manufacturing Sites - Active Pharmaceutical Ingredients
Manufacturing Sites < Active ‘ naceutical Ingredients age : “
Slide 10: Manufacturing Sites - APIs
rom) Onyx Scientific (Sunderland) WD Apis and / or intermediates @ rao B® Biotech WD Corporate Office Pisgah Labs (Pisgah, NC) IpcaLaboratories *Unichem Laboratories * Krebs Biochemicals Indore Cluster Hingni ° , Baroda Cluster Mumbai Cluster Mumbai.. Mum! Manufacturing Sites APIs > Chh, Sambhajinag
Slide 11: Manufacturing Sites - APIs
Manufacturing Sites APIs [ Location | Inspections / Approvals by Agencies of ] e@ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO © Indore Madhya Pradesh) nig B,WHO @ Dewas (Madhya Pradesh) EU, India, Russia © Nandesari Gujrat) Ind
Slide 12: Revenue Break-up
Reven ue Break- -up
Slide 13: Revenue Break-up
Revenue Break-up Standalone 2025-26 Total Total Revenue Exports Domestic 2025-26 2025-26 2025-26 2025-26 e e e e Formulations: APIs Formulations e APIs Formulations : Export Domestic : APIs @ Formulations @ APIs @ Domestic @ Exports @ Formulations @® APIs @ Formulations @® APIs
Slide 14: Revenue Break-up
Revenue Break-up Standalone 2025-26 2024-25 Crs | Domestic | Exports | Total | Domestic | Exports | Total Growth | @ Branded Formulations 3,817.24 663.67 4,480.91 3,450.21 581.89 4,032.10 4 pen isiton/ - 14891 1,418.91 4389 1,336.69 1341.58 © Total Formulations 3,817.24 2,082.58 5,899.82 3,455.10 1,
Slide 15: Standalone
Standalone FY 2025-26 FY 2024-25 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 7,431.39 839 6,749.21 — e EBIDT 1,847.36 209 1,513.33 e EBIDT% 25.18% - 22.66% @ PBT* 1,562.55 116 1,281.31 e@ PBT% 21.30% - 19.19% @ PAT* 1,132.52 128 650.76 @ PAT% 15.44% - 9.74% # After forex loss of €67.07 Crs
Slide 16: Financials - Standalone
Financials Standalone CO Profitability | FY 2025-26 FY 2024-25 @ point WB Pst WB PAT @ point WB Pst WB PAT
Slide 17: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 18: Financials - Standalone
Financials Standalone FY 2025-26 FY 2024-25 @ Net Profit 74.0% 22.7%
Slide 19: Consolidated Financials
FY 2025-26 FY 2024-25 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 9,820.78 1,109.07 9,032.39 1,067 e EBIDT 1,998.96 226 1,693.13 200 e@ EBIDT% 20.72% - 18.94% - Po @ PBT* 1,658.95 187 1,336.19 158 @ PBT% 17.20% - 14.95% - po @ PAT* 1,141.12 128.87 737.68 87 # After forex loss of $20.40 Crs a
Slide 20: Financials - Consolidated
Financials Consolidated Business Characteristics FY 2025-26 FY 2024-25 Return on Capital Employed % (PBIT / Capital Employed) 17.25% 14.98% Return on Net Worth % (PAT / Net Worth) 14.15% 10.62% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 1.82 1.85 Capital Employed Turnover Ratio (To
Slide 21: Financials - Consolidated
Financials Consolidated FY 2025-26 FY 2024-25 © Net Profit 54.7% 34.8%
Slide 22: Contribution of Therapeutic Groups
Financials Standalone Contribution of Therapeutic Groups a Therapeutic Segment — 2025-26 Domestic 2024-25 00 © Cardiovasculars& Anti-Diabetics es re © AntiMalarials e % 3% © Gastonia (GPoduts BH © Neuro Psychiatry e 4% 3% © Cough Preparations Ba © Dermatology e 6% 6% © Uren HH © ‘Neutraceuticas e %
Slide 23: Branded Formulations
Branded| Formulations
Slide 24: Branded Formulations - Domestic
Branded Formulations a Domestic . 22 Market leaders in All India Rank IQVIA Therapy Focused Over 4000 Rheumatoid Arthritis 16" (MAT Mar’26) Marketing Divisions Wholesalers & Anti-malarials Gy @ 24 Depots & Field Strength 6 brands among ‘1 C&F agent (PSR/ BA)-7162 top 300 brands (Zerodol-SP, Zerodol-
Slide 25: Branded Formulations - Domestic
Branded Formulations Domestic ( %3,817.24 4000 3,455.10 oes) 3,097.16 ($408 Mn) 3500 2,760.71 ($374Mn) 3000 (5344 Mn) 2500 2000 1500 1000 0 —O— 2025-26 o ' T T 1 2022-23 2023-24 Ne 2022-23 2023-24 2024-25 2025-26 ) 3004.25 Figures in Crores. Sales
Slide 26: Future Growth Drivers - Domestic
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS rail [—® Strong brand building with focused promotion -—e In-licensing / out-licensing to build business in the promoted therapy Portfolio optimisation, strategies to
Slide 27: International
\ Intern ational
Slide 28: International Business
International Business a Registrations in 61 countries © Recognised _A Field-force to promote brands © Five Star Export gu in more than House 30 countries Products of the company 42% sales & Marketing offices in are now exported to over From exports By 12 countries 100 countries across the globe
Slide 29: International Business
International Business (— 3500 %312943 ) 353 Mn) €2,808.96 2,707.70 " 3000 %2,643.42 5 ($332 Mn) (5330 Mn) (22480) 2500 2000 1500 1000 500 —O— 2025-26 0 T T 1 1 2022-23 L 2022-23 2023-24 2024-25 2025-26 ) O- 202324 Figures in Crores. Sales 29
Slide 30: International Business
International Business a Continent-wise Exports 2025-26 (%Crs) Continent Formulations APIs | Total | % Contribution © Europe 522.75 361.84 884,59 28% © Africa 538.56 55.92 594.48 19% © Americas 344.03 321.30 665.33 21% © Asia 134.66 263.51 398.17 13% e dls 228.21 40.97 269.18 9% © Australasia 314.37
Slide 31: Slide 31
Slide 32: International Formulations
International Formulations %2,082.58 31,918.58 ($235 Mn) ($227 Mn) 21,775.32 21,639.19 ($214Mn) ($204 Mn) XX 2022-23 2023-24 2024-25 2025-26 ~ w —O— 2025-26 2022-23 2023-24 2024-25 Figures in Crores. Sales
Slide 33: International
Intern ational
Slide 34: International Branded Formulations
International Branded Formulations ( 663.67 > 690 ($75 Mn) 660 630 %581.89 600 (569Mn) 570 526.70 540 %504.79 (564M) 510 (563 Mn) 480 450 420 390 360 —O— 2025-26 330 T T T 1 2022-23 L 2022-23 2023-24 2024-25 2025-26 —O- 202324 Figures in Crores. Sales
Slide 35: Future Growth Drivers - Branded Formulations
International Branded Formulations Future Growth _ Thrust on brand building in Pain, CVS, CNS, Anti-infective Drivers and Anti-malarial segments ral —® Geographical expansion in covered countries through additional field force ‘—® Expansion in business lines - Institutions and Distributors Introduct
Slide 36: International - Generics / Institution / Tender
@ eo ae tional NS nstitution / Tender so Ane SS 5
Slide 37: International Generics / Institution / Tender
International Generics / Institution / Tender >) Count Products Products Under 1600 T1,418.91 ountry Registered Registration 1,336.69 (Gy) 1400 1,248.62 (sist) United Kingdom ($151 Mn) 60 5 1200 21,134.40 / Europe Crain} Australia / i 2 1000 New Zealand 800 South Africa 53 10 600 United States / Can
Slide 38: International Generics - Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries al Formulations registered to be backed by own API Sale of generic dossiers with or without supply agreements Contract manufacturing arrangements Future Gr
Slide 39: International - APIs
internat ational
Slide 40: International APIs
International ~ APIs 1200 1,046.85 1,004.23 ($118 Mn) Spy ie %390.38 in le 1000 (5105 Nin) 800 600 400 200 —O— 2025-26 0 202-8 L 2022-23 2023-24 2024-25 2025-26 ) eos Figures in Crores. Sales 40
Slide 41: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API US-FDA Canada- wHo | /Pa% | Australia| EQDM 1 1 Alendronate Sodium () cs - 7) - i} 2 2 Allopurinol (7) @ = = CEP @ 3 3 Amlodipine Besylate () = - - z 4 Amlodipine Besylate (AK4 Process) - - - = ° Gg 4 5 Amodiaquine HCI = S @ - - - 5 6 A
Slide 42: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 11 12 12 13 13 14 14 15 15 16 16 7 18 17 19 18 20 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Bupropion Hydrochloride Carvedilol Celecoxib Cetrizine Hydrochloride Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlorthalidone (CT3
Slide 43: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API US-FDA Canada- wHo | /Pa% | Australia| EQDM 20 23 Citalopram HBR - = = o - @ 21 24 Dihydroartemesinin = S Gg - - - 22 25 Donepezil Hydrochloride Monohydrate - - - - - @ 23 26 —_ Duolexitine Hydrochloride (7) - = 2 - 7) 24 27 Entacapone
Slide 44: APIs - Drug Master Files
International APIs - Drug Master Files oA. OME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 29 34 ~—‘*Frusemide () Vv] - G@ ceP G@ 30 35 Fluoxetine HCI (7) - - - - @ 31 36 ~—‘Felodipine 2 2 2 2 : Gg 3237s Glimepiride g : : g@ : i) 38 Hydrochlorothiazide (Process I) (7) @ - g@ CEP Gg 3
Slide 45: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 38 45 Lamotrigine - = = o - (7) = 46 Losartan Potassium (LB4 Process) (7) - 2 2 - (7) 47 Losartan Potassium (LB7 Process) = Gg - - = () 40 48 Lumefantrine = = @ - - . 41 49 ~~ Meloxicam () : - -
Slide 46: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 56 47 57 48 58 59 49 60 50 61 51 62 52 63 53 64 54 65 55 66 Name of the API Metoclopramide HCI Metoclopramide HCl (M Process) Metoprolol Succinate Metoprolol Tartrate Metoprolol Tartrate (03 / 05 Process) Midodrine Hydrochloride Nifedipine Olanzapine Ondansetron Base Ondan
Slide 47: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 56 67 57 68 58 69 59 70 60 71 61 72 62 73 63 m 75 64 76 65 77 Name of the API Piperaquine Phosphate Primaquine Phosphate Proguanil Hydrochloride Propranolol HCI Pyrantel Embonate Pyrantel Pamoate Pyrimethamine Quetiapine Fumarate Quetiapine Fumarate (QT5 Process) Risendron
Slide 48: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 78 Telmisartan - = 2 - - @ 66 79 Telmisartan (WT6 Process) - - - = 2 g@ 80 _Telmisartan (WT3A Process) (7) - = 2 - . 67 81 Torsemide (7) - = o - Qo 68 82 Tramadol Hydrochloride (YT3 Process) - -
Slide 49: International APIs - Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe Future Growth Drivers —e Long term strategic tie-ups with major South American / European formulators Leverage the customer base of more than 1000 customers spread across 90 _A countries is well laid down platform to introdu
Slide 50: Research & Development
AS Resear rh& Development
Slide 51: Research & Development - APIs & Formulations
Research & Development AP\s & Formulations ( 260 73081 450% ) Year | Xrs | sta saes | nae , 2021-22 141.46 2.63% 230 %207.08 4.00% 210 3.12% 3.50% 2022-23 156.49 71% ao sry 6 ere “lon ° EM 2023-24 161.50 2.64% 150 2.50% rn) er 2024-25 207.08 3.12% 90 1.50% 2025-26 239.81 3.29% 60 1.00% 30 0.50% —O—
Slide 52: Research & Development - APIs & Formulations
Research & Development APls & Formulations -—® Current scientist manpower of 650+ Research focus on developing APIs with non-infringing process and development of finished dosage forms Development of NDDS for domestic and international market 286 patent applications filed Biotech / fermentation rese
Slide 53: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialisation” Single-use CGMP Bio-manufacturing Facility (DS+-DP+0QC) with 500 and 2000L capacity for clinical
Slide 54: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines Molecules: Anti-cancer , Anti-inflammatory and Ophthalmic mAbs Stage of Development [ Molecules e 7 Monoclonal antibodies (mAbs) and One Non- MAA/ Launch mAb Biosimilar at various stages of the development UK/CA/IN/EU © Target markets India, UK, CA, EU, ROW /USA followed
Slide 55: Thank You